Overview

Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531

Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
To assess the safety and tolerability of ascending multiple oral doses of SAM-531, an investigational drug, in healthy Japanese young male and elderly subjects.To provide the pharmacokinetics (PK) and pharmacodynamics (PD) profiles of multiple oral doses of SAM-531 in healthy Japanese young male and elderly subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer